WO2009007674A3 - Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast - Google Patents
Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast Download PDFInfo
- Publication number
- WO2009007674A3 WO2009007674A3 PCT/GB2008/002188 GB2008002188W WO2009007674A3 WO 2009007674 A3 WO2009007674 A3 WO 2009007674A3 GB 2008002188 W GB2008002188 W GB 2008002188W WO 2009007674 A3 WO2009007674 A3 WO 2009007674A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seratrodast
- ramatroban
- atherosclerosis
- treatment
- mast cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
There is provided combination products comprising (a) a mast cell inhibitor, or a pharmaceutically-acceptable salt or solvate thereof; and (b) ramatroban or seratrodast, or a pharmaceutically-acceptable salt or solvate of either of those compounds. Such combination products find particular utility in the treatment of atherosclerosis and related conditions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92972607P | 2007-07-11 | 2007-07-11 | |
US60/929,726 | 2007-07-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009007674A2 WO2009007674A2 (en) | 2009-01-15 |
WO2009007674A3 true WO2009007674A3 (en) | 2009-03-19 |
Family
ID=38707246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2008/002188 WO2009007674A2 (en) | 2007-07-11 | 2008-06-25 | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009007674A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106404930A (en) * | 2016-08-19 | 2017-02-15 | 苏州大学附属第二医院 | Method for determination of concentration of 5, 6-dihydro-7,8-dimethyl-4,5-dioxy-4-H-pyranoquinoline-2-carboxylic acid in plasma |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009122183A1 (en) * | 2008-04-04 | 2009-10-08 | Cardoz Ab | New combination for use in the treatment of inflammatory disorders |
WO2009122182A1 (en) * | 2008-04-04 | 2009-10-08 | Cardoz Ab | New combination for use in the treatment of inflammatory disorders |
WO2009122181A1 (en) * | 2008-04-04 | 2009-10-08 | Cardoz Ab | New combination for use in the treatment of inflammatory disorders |
EP2303251B1 (en) * | 2008-04-07 | 2012-05-16 | Cardoz AB | New combination for use in the treatment of inflammatory disorders |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4086349A (en) * | 1975-07-30 | 1978-04-25 | Mitsubishi Yuka Pharmaceutical Co., Ltd. | Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma |
US4965258A (en) * | 1986-02-21 | 1990-10-23 | Bayer Aktiengesellschaft | Cycloalkano(1,2-B)indole-sulphonamides, pharmaceutical compositions and use |
US6020380A (en) * | 1998-11-25 | 2000-02-01 | Tap Holdings Inc. | Method of treating chronic obstructive pulmonary disease |
US6362214B1 (en) * | 1997-12-24 | 2002-03-26 | Bayer Yakuhin, Ltd. | Thermodynamically stable form of (R)-3-[[(4-fluorophenyl) sulphonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid (ramatroban) |
US20020103219A1 (en) * | 2000-10-05 | 2002-08-01 | Jeremy Jacob | Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders |
-
2008
- 2008-06-25 WO PCT/GB2008/002188 patent/WO2009007674A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4086349A (en) * | 1975-07-30 | 1978-04-25 | Mitsubishi Yuka Pharmaceutical Co., Ltd. | Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma |
US4965258A (en) * | 1986-02-21 | 1990-10-23 | Bayer Aktiengesellschaft | Cycloalkano(1,2-B)indole-sulphonamides, pharmaceutical compositions and use |
US6362214B1 (en) * | 1997-12-24 | 2002-03-26 | Bayer Yakuhin, Ltd. | Thermodynamically stable form of (R)-3-[[(4-fluorophenyl) sulphonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid (ramatroban) |
US6020380A (en) * | 1998-11-25 | 2000-02-01 | Tap Holdings Inc. | Method of treating chronic obstructive pulmonary disease |
US20020103219A1 (en) * | 2000-10-05 | 2002-08-01 | Jeremy Jacob | Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders |
Non-Patent Citations (16)
Title |
---|
DOGNE J-M ET AL: "Recent developments of thromboxane modulators", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 11, no. 11, 2001, pages 1663 - 1675, XP002445841, ISSN: 1354-3776 * |
HORIGUCHI T ET AL: "Study on the usefulness of seratrodast in the treatment of chronic pulmonary emphysema", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 52, no. 10, 2002, pages 764 - 768, XP002998194, ISSN: 0004-4172 * |
ISAJI M ET AL: "TRANILAST INHIBITS THE PROLIFERATION, CHEMOTAXIS AND TUBE FORMATIONOF HUMAN MICROVASCULAR ENDOTHELIAL CELLS IN VITRO AND ANGIOGENESIS IN VIVO", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 122, no. 6, November 1997 (1997-11-01), pages 1061 - 1066, XP000997892, ISSN: 0007-1188 * |
ISHIZUKA T ET AL: "RAMATROBAN (BAY U 3405): A NOVEL DUAL ANTAGONIST OF TXA2 RECEPTOR AND CRTH2, A NEWLY IDENTIFIED PROSTAGLANDIN D2 RECEPTOR", CARDIOVASCULAR DRUG REVIEWS, NEVA PRESS, BRANFORD, CT, US, vol. 22, no. 2, June 2004 (2004-06-01), pages 71 - 90, XP008078031, ISSN: 0897-5957 * |
ISHIZUKA T: "THROMBOXANE A2 RECEPTOR BLOCKADE PREVENTS ATHEROSCLEROTIC PROCESS BY ITS ANTI-INFLAMMATORY EFFECT", VASCULAR DISEASE PREVENTION, BENTHAM SCIENCE PUBLISHERS, GB, vol. 3, no. 2, May 2006 (2006-05-01), pages 143 - 148, XP008078040, ISSN: 1567-2700 * |
JONES N L ET AL: "Ketotifen therapy for acute ulcerative colitis in children: A pilot study", DIGESTIVE DISEASES AND SCIENCES, PLENUM PUBLISHING CO, US, vol. 43, no. 3, 1 March 1998 (1998-03-01), pages 609 - 615, XP008086243, ISSN: 0163-2116 * |
MARSHALL J K ET AL: "Ketotifen treatment of active colitis in patients with 5-aminosalicylate intolerance", CANADIAN JOURNAL OF GASTROENTEROLOGY, MEDICARE PUBL., OAKVILLE, CA, vol. 12, no. 4, 1998, pages 273 - 275, XP008086245, ISSN: 0835-7900 * |
MATSUMURA ET AL: "Suppression of atherosclerotic development in watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast", MEDLINE, 23 February 1999 (1999-02-23), XP002953929 * |
MINOCHA A ET AL: "Role of ketotifen in pathogenesis of chronic ulcerative colitis", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 104, no. 4 SUPPL, 1993, pages A746, XP008086242, ISSN: 0016-5085 * |
NOBUHIDE O ET AL: "Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease", GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, GB, vol. 56, no. 4, April 2007 (2007-04-01), pages 599 - 600, XP008086231, ISSN: 0017-5749 * |
SAIURA A ET AL: "Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 433, no. 2-3, 21 December 2001 (2001-12-21), pages 163 - 168, XP008086230, ISSN: 0014-2999 * |
SAMARA E E: "Seratrodast (AA-2414). A novel thromboxane-A-2 receptor antagonist", CARDIOVASCULAR DRUG REVIEWS, NEVA PRESS, BRANFORD, CT, US, vol. 14, no. 3, 1996, pages 272 - 285, XP008082200, ISSN: 0897-5957 * |
SHIMIZU T ET AL: "INHIBITORY EFFECTS OF AZELASTINE AND TRANILAST ON LEUKOTRIENE B4 AND LEUKOTRIENE C4, GENERATION BY RAT COLONIC MUCOSA", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE MEDICAL JOURNALS,, GB, vol. 53, no. 5, 1995, pages 355 - 358, XP001042184, ISSN: 0952-3278 * |
TEH L G ET AL: "Does the addition of ketotifen to non-steroidal anti-inflammatory drugs confer any additional benefit in rheumatoid arthritis?", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, BLACKWELL SCIENTIFIC PUBL, GB, vol. 17, no. 2, 1984, pages 157 - 159, XP008086082, ISSN: 0306-5251 * |
YAMADA N ET AL: "MY-1250, a major metabolite of the anti-allergic drug repirinast, induces phosphorylation of a 78-kDa protein in rat mast cells", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 44, no. 6, 25 September 1992 (1992-09-25), pages 1211 - 1213, XP023732179, ISSN: 0006-2952, [retrieved on 19920925] * |
ZHANG W ET AL: "Development of new therapeutic effect and mechanism of tranilast", ZHONGGUO XIN YAO YU LINCHUANG ZAZHI - CHINESE JOURNAL OF NEW DRUGS AND CLINICAL REMEDIES, SHANGHAI SHI YIYAO GUANLIJU KE-JI QINGBAO YANJIUSUO ZHONGGUO, CN, vol. 23, no. 11, November 2004 (2004-11-01), pages 795 - 798, XP008086232, ISSN: 1007-7669 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106404930A (en) * | 2016-08-19 | 2017-02-15 | 苏州大学附属第二医院 | Method for determination of concentration of 5, 6-dihydro-7,8-dimethyl-4,5-dioxy-4-H-pyranoquinoline-2-carboxylic acid in plasma |
CN106404930B (en) * | 2016-08-19 | 2018-08-17 | 苏州大学附属第二医院 | A kind of method of 5,6- dihydro -7,8- dimethyl -4,5- dioxies -4- hydrogen-pyranoquinoline -2- carboxylic acid concentrations in measurement blood plasma |
Also Published As
Publication number | Publication date |
---|---|
WO2009007674A2 (en) | 2009-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009007673A3 (en) | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist | |
EP2497470B8 (en) | Imidazotriazines and imidazopyrimidines as kinase inhibitors | |
WO2009007675A3 (en) | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist | |
WO2009007674A3 (en) | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast | |
AU2008246443A8 (en) | 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase | |
WO2009007679A3 (en) | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist | |
AU2007337830A8 (en) | Benzenesulfonamide derivatives as HIV protease inhibitors | |
MX2009006507A (en) | New combination for use in the treatment of inflammatory disorders. | |
WO2008118409A3 (en) | Bone screw apparatus and related methods of use | |
IL201168A0 (en) | New combination for use in the treatment of inflammatory disorders | |
WO2009007680A3 (en) | Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders | |
GB0502669D0 (en) | Swivel laptop/utility table | |
EP1794107B8 (en) | Sulfonated nitrophenols as polymerization inhibitors | |
AU2004202621A1 (en) | Water saver adaptor | |
AU2006903310A0 (en) | Notebook computer stand | |
AU2006905290A0 (en) | Fast minkowski hull operations | |
AU2006906611A0 (en) | Portable computer | |
AU2005100796A4 (en) | Hexagonal Rotating Pool Table | |
AU2005905018A0 (en) | Liquid handling equipment | |
AU2006904441A0 (en) | Wine preservation | |
AU2005903118A0 (en) | Storage vessels | |
AU2007904416A0 (en) | Notebook Computer Stand | |
AU2007904269A0 (en) | Notebook Computer Stand | |
AU2007900713A0 (en) | Portable universal turn table (P.U.T.T.) | |
AU2006903693A0 (en) | Quadra bench |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08762494 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08762494 Country of ref document: EP Kind code of ref document: A2 |